Analogs of vancomycin and pseudo-vancomycin with new sugar attachments in mono-and di-saccharide form have been enzymatically synthesized by glycosylation with overexpressed glycosyltransferases, b1,4-galactosyltransferase and a2,3-sialyl transferases. All four analogs, including galactose-containing derivatives (6 and 8) and galactose-and sialic acid-containing derivatives (7 and 9) were prepared and characterized by HPLC, LC-MS, NMR and MIC test.
INTRODUCTION
Vancomycin (1) belongs to the glycopeptide class of antibiotics, which are effective in the treatment of life-threatening methicillin-resistant Gram-positive bacterial infections, and more importantly, it is useful in the treatment of clinically resistant Staphylococcus aureus. As shown in Figure 1 , has two hexoses attached as an L-vancosaminyl-1,2-Dglucosyl disaccharide to residue four, 4-hydroxyphenylglycine, of the heptapeptide scaffold. 1, 2 The desvancosamine derivative of vancomycin, pseudo-vancomycin (2), which is 2-4 times less active than the parent antibiotic, was obtained as the major product by treatment with trifluoroacetic acid. 3 Recent enzymatic and chemoenzymatic alterations have revealed that vancomycin's disaccharide attachment may be one alteration route for new bioactive compounds. 4, 5 Walsh group and coworkers showed regio-specific enzymatic reconstitution of the antibiotic chloroeremomycin from the heptapeptide aglycone by three glycosyltransferases, GtfA, GtfB and GtfC, 6 and a systematic utility of chemoenzymatic approaches to diversify complex natural product architectures by using glycopeptides glycosyltransferases, GtfD and GtfE, which are the most versatile enzyme for the synthesis of vancomycin analogs. 7, 8 Glycosyltransferases have proven to be of great importance in oligosaccharide biosynthesis. One glycosyltransferase gene, HP0826, encodes the b1,4-galactosyltransferase (b1,4-GalT, EC 2.4.2.22) involved in the biosynthesis of the lipopolysaccharide O-chain backbone of Helicobacter pylori. It was cloned nearly a decade ago and demonstrated that HP0826 has a highly efficient activity for the synthesis of trisaccharides (Gala1, 4Galb1, 4GlcNAc) with recombinant bacteria. [9] [10] [11] Another glycosyltransferase gene, Pm0188, which encodes multifunctional sialyl transferases (SiaTs), was cloned from Pasteurella multocida genomic strain Pm70 and four functions, such as a2,3-SiaT, a2,6-SiaT, sialidase and trans-sialidase, have been identified. 12 Especially, a2,3-SiaT can transfer a sialic acid (Sia) residue from CMP-Sia to galactosides to form a2,3 sialyl linkages efficiently at a wide range of pH values (pH 7.5-9.0). In addition, a highly active b1,4-GalT and a2,3-SiaT with broad substrate specificity will be a powerful tool for broadening the application of enzymatic approaches to synthesizing the structurally modified glycone of 1.
To explore new vancomycin analogs with a glycan chain, we report the incorporation of galactose and Sia by enzymatic glycosylations onto D-glucose of 1 and 2 using two purified enzymes, b1,4-GalT and a2,3-SiaT. In addition, MIC test of these analogs were then examined for antibiotic activity.
RESULTS
Overexpression and purification of b1,4-GalT and a2,3-SiaT The PCR products were cloned into the NdeI/HindIII sites of the pET32a(+) expression vector under the control of the T7 promoter. These recombinants were transferred and expressed as full-length enzymes in a heterologous host strain, E. coli BL21(DE3). Expression with C-terminal His 6 -tagged fusion proteins in soluble form was achieved at 20 1C with 1.0 mM isopropyl b-D-thiogalactopyranoside (data not shown). During the purification process with Co 2+ affinity chromatography, the target proteins were completely eluted at a concentration of 100 mM imidazole. The molecular weight of the proteins observed by 12% SDS-PAGE analysis was in good agreement with those of calculated values as 32-kDa (b1,4-GalT) and 53-kDa (a2,3-SiaT) (Figures 2b and c) , and their contents after purification were found to be 21.19 nmol ml À1 and 16.28 nmol ml À1 , respectively.
Proving the enzymatic activity of b1,4-GalT and a2,3-SiaT on N-acetylglucosamine Attempts to overexpress b1,4-GalT and a2,3-SiaT were made in the enzymatic synthesis of 4 and 5 from 3 to construct novel glycosylated vancomycin derivatives that could be directly modified to synthesize glycopeptide analogs (Figure 2a ). The galactosylation reaction was carried out on a 30-ml scale with UDP-Gal. After 24 h, 4 was isolated through several purification steps involving the use of DOWEX 1X8- Enzymatic glycosylations using b1,4GalT and a2,3SiaT
T-J Oh et al 200 chloride anion-exchange resin and sephadex G10 resin from the reaction mixture. In addition, the sialylation reaction containing CMP-NeuAc and the purified a2,3-SiaT was performed on the purified disaccharide 4. The reaction was allowed to proceed for 12 h, and then 5 was isolated through several steps of purification, including activated charcoal chromatography. To obtain a pure sample, the compound was further purified using DOWEX 1X8-200-chloride anion-exchange resin and sephadex G10 resin. As described in the Methods section, MS ( Figure 2d ) and NMR analyses (data not shown) confirmed the structural identity of 5. MS analysis of isolated compound 5 showed m/z¼673.2 [M-H] À , which is identical to the authentic trisaccharide. These results indicated that coupling the trisaccharide 5 production system and overexpressed proteins (b1,4-GalT from H. pylori and a2,3-SiaT from P. multocida) worked very well and suggested that this technique could be applied to the other compounds.
Enzymatic synthesis and analysis of novel glycosylated compounds from pseudo-vancomycin and vancomycin Compound 2, which was prepared by trifluoroacetic acid-treated cleavage of the monosaccharide, 3 was enzymatically galactosylated with the overexpressed b1,4-GalT using UDP-Gal as the glycosyl donor ( Figure 3a ) to generate compound 6. Then the sialylation of 6 was carried out using overexpressed a2,3-SiaT and CMP-NueAc for compound 7. Glycosylated compounds 6 and 7 were monitored with HPLC analysis (Hypersil ODS) at r. Figure 3c) . Similarly, the glycosylations of 1 were investigated using overexpressed b1,4-GalT and a2,3-SiaT, as shown above (Figure 4a ). The glycosylated compounds 8 and 9 were also monitored using HPLC analysis (Chromolith performance) at r.t. for 9.2 and 9.6 min, respectively, and compared with 1 (r.t. 10.6 min). Substrate conversion yields, 61 and 50% were observed after 20 h and 90 min, respectively ( Figure 4b ). MS analysis revealed that the molecular ions MW/2 for 8 and 9 were detected at m/z ¼ 805.
respectively, at r.t. (Figure 4c ).
NMR spectroscopy
The structure elucidations of pseudo-vancomycin (2), 6 and 7 were achieved by use of 2D 1 H-1 H COSY and 1 H-1 H TOCSY spectroscopy. The chemical shifts observed in the proton NMR closely related to vancomycin (1) in the published data without sugar residues. The glucose of pseudo-vancomycin was assigned to d 5.18 were observed in compound 7. The anomeric protons (1-CH) of glucose and galactose of 6 and 7 were observed with minor shift (Table 1) . Enzymatic glycosylations using b1,4GalT and a2,3SiaT
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Biological activity assays of vancomycin analogs MIC tests were performed by CCARM in accordance with the CLSI guidelines. All enzymatically synthesized vancomycin derivatives purified by preparative HPLC and standard vancomycin were assayed against 20 Gram-positive strains, including MSSA, MRSA, VISA, VREF and VSEF. As shown in Table 2 , natural vancomycin was active against several S. aureus and E. faecalis (CCARM no. 5108) strains, with MIC values in the range of 1-4 mg ml À1 for MSSA, MRSA, VISA and 2 mg ml À1 for VSEF. In addition, vancomycin was inactive against several VREF strains containing vanA or vanB genes (MIC4128 mg ml À1 ). The pseudo-vancomycin derivative (6) containing galactose, exhibited poor activity against MSSA, MRSA, VISA and VSEF (MIC¼4-16 mg ml À1 ), but was inactive against VREF, as was 1. Furthermore, galactosylation of vancomycin antibiotics (8) Enzymatic glycosylations using b1,4GalT and a2,3SiaT T-J Oh et al a significant factor in the improvement of activity against vancomycin-resistant enterococci. 13, 14 Therefore, the ability to generate additional sugar variants of vancomycin by using dedicated glycosyltransferases would be of particular interest. Diversification of vancomycin through chemoenzymatic strategies to identify new derivatives with novel biological activities has been a practical process; however, these strategies have several limitations, including difficulty synthesizing the sugar donor and substrate specificity. 8, 15 This approach is more convenient than traditional chemical glycosylation of the vancomycin aglycon due to the protection of the aglycon before glycosylation. 16 The diversity of glycones that can be enzymatically incorporated into the vancomycin aglycon also was reduced in other groups through enzymatic glycosylation with their own glycosyltransferases, GtfE, GtfD, GtfC and GtfA. [5] [6] [7] 17 Likewise, we have established that the procedure involving enzymatic glycosylation with both the b1,4-GalT and a2,3-SiaT cloned from different origins (H. pylori and P. multocida, respectively) and subsequent purification after heterologous expression in E. coli is useful for altering the di-and trisaccharyl chains of vancomycin. The b1,4-GalT gene involved in the biosynthesis of lipopolysaccharides in H. pylori has been cloned and expressed in E. coli, and it was also confirmed that b1,4-GalT catalyzed the introduction of galactose from UDP-Gal in a b1,4 linkage to accept residues from 3. 9,10 Thus, Wang's group already showed that enzymatic synthesis of the P1 trisaccharide (Gala1,4Galb1,4GlcNAc), an oligosaccharide analogue, was assessed with H. pylori b1,4-GalT and Neisseria meningitides a1,4-GalT. 11 Those studies provide an efficient approach, including the substrate flexibility of b1,4-GalT, for the galactosylation of other molecules. In addition, the Pm0188 gene from P. multocida has been cloned, and a truncated protein (tPm0188Ph) was expressed in E. coli. 12 They identified its pH-dependent four types of multifunctional activity containing an a2,3-SiaT (pH 7.5-9.0), an a2,6-SiaT (pH 4.5-7.0), a sialidase (pH 5.0-5.5), and a trans-sialidase (pH 5.5-6.5). They also showed that a2,3-SiaT has relaxed acceptor specificity on galactose and b-galactosides. The finding that these kinds of series work strongly supports the possibility of glycosylating galactose and Sia onto D-glucose of 1 and 2 using two purified enzymes, b1,4-GalT and a2,3-SiaT.
In this study, we began with enzymatic synthesis of the trisaccharide (NeuAca2,3Galb1,4GlcNAc, 5) using two overexpressed glycosyltransferases, b1,4-GalT and a2,3-SiaT, to compound 3, which allowed us to investigate their activities. With the expected substrate specificity of the two glycosyltransferases, continuous galactosylation and sialylation reactions resulted in the incorporation of galactose and Sia to generate derivatives 4 and 5, respectively. The productions of 4 and 5 were yielded at recovery rates of 91 and 79%, respectively, and this result was also confirmed by MS analyses. The key condition for the enzymatic synthesis of 5 is the use of a buffer at a pH of 8.5 for optimal a2,3-SiaT activity. Owing to the relaxed substrate specificity described above, we focused second on the actions of b1,4-GalT and a2,3-SiaT on compound 1 and 2, using a slightly modified methodology. Our results showed that both enzymes are promiscuous for the transfer of galactose and Sia to the natural acceptors with high substrate conversion yields (6, 82%; 7, 75%; 8, 61%; 9, 50%). All vancomycin derivatives were confirmed by HPLC, MS and NMR analyses. In addition to the difference in production yield between galactosylation and sialylation, the overall turnover rates from 2 were relatively faster than those from 1.
All enzymatically synthesized derivatives were tested by in vitro MIC assays, and they showed antibiotic activity against the MRSA and VSEF strains, with the galactose-containing vancomycin derivative (8) having the best MIC values (0.5-1 mg ml À1 ). All other derivatives, including 7 and 9, showed no activity against the MSSA, MRSA, VISA, VREF and VSEF strains in vitro, although the galactose-containing pseudo-vancomycin derivative (6) had the least favorable MIC values. Finally, it is interesting to note that galactose-containing derivatives maintain or improve the antibiotic activity, whereas the galactose/Siacontaining derivatives diminish the activity against resistant strains. Although the exact activity of our derivatives (6-9) remains to be determined, these results are in agreement with earlier results regarding the influence of sugars with regards to their solubility, dimerization constants and conformational flexibility of the aglycon scaffold involved in naturally occurring glycopeptide antibiotics. 18, 19 It is also possible that these vancomycin derivatives containing galactose inhibit transglycosylation by decreasing the affinity to the substrate, and Sia-containing structures will have important roles in cellular recognition and communication because of the anion charge of Sia when they transfer into the cell. 20, 21 Further inhibition studies of our derivatives are required to understand their mechanisms of action in resistant strains. In summary, we used an enzymatic approach to generate novel vancomycin derivatives using two glycosyltransferases (b1,4-GalT and a2,3-SiaT) from other origins and demonstrated the incorporation of galactose and Sia onto the D-glucose glycone of both vancomycin and pseudo-vancomycin. In addition, the MIC test results showed that the antibiotic activities of galactose-containing derivatives against the MRSA and VSEF are the same or better than those of galactose/Siacontaining derivatives. This enzymatic glycosylation strategy utilizing the relaxed substrate specificity of glycosyltransferases, b1,4-GalT and a2,3-SiaT, may also be applicable to other glycopeptide antibiotics and other glycosylated natural small molecules, including polyketide and nonribosomal peptide.
METHODS Materials
Escherichia coli XL1-blue MRF was used as a host cell for the preparation of recombinants plasmids, and E. coli BL21(DE3) (Stratagene, La Jolla, CA, USA) was used for the expression of the enzyme. They are typically cultured in LuriaBertani broth or on Luria-Bertani agar plates at 37 1C. 22 Standard vancomycin (GCBA0009, 1) and pseudo-vancomycin (GCBC0016, 2) were purchased from GeneChem (Daejeon, Korea). UDP-galactose (UDP-Gal, U4500), CMP-Nacetylneuraminic acid (CMP-NeuAc, C8271) and N-acetylglucosamine (GlcNAc, A8625, 3) were purchased from Sigma (St Louis, MO, USA). Oligonucleotide primers were synthesized at Geno-Tech (Daejeon, Korea), and all enzymes were purchased from Takara (Kyoto, Japan). The pGEM-T easy vector (Promega, Madison, WI, USA) and pET32a(+) (Novagen, Darmstadt, Germany) were used as vectors for gene cloning and expression, respectively. b1,4-GalT and a2,3-SiaT were amplified by polymerase chain reaction (PCR) using the genomic DNA of H. pylori (ATCC 43504) and P. multocida Pm70 (ATCC 15742), respectively, as a template. PCR was performed on a PCR Thermal Cycler (Takara, Japan), and the PCR products were cloned under the control of the T7 promoter.
Expression and purification of b1,4-GalT and a2,3-SiaT
The cloning and expression procedures for b1,4-GalT and a2,3-SiaT were performed according to the standard protocol. 22 b1,4-GalT was amplified by PCR with the set of modified primers harboring forward Gal-f (5¢-TATCAT ATGCGTGTTTTTATCATTTC-3¢) and reverse Gal-r (5¢-GCAAGCTTTACAA ACTGCCAATATTTC-3¢). The primers, Sia-f (5¢-TATCATATGAAAACAATCA CGC-3¢) and Sia-r (5¢-GCAAGCTTCAACTGTTTTAAACTG-3¢), were used to clone a2,3-SiaT. The restriction sites are indicated by underlined letters. To confirm that there was no mutation, all PCR products (b1,4-GalT, 822 bp; and a2,3-SiaT, 1,167 bp) were cloned into the pGEM-T easy vector and sequenced before cloning into the NdeI and HindIII site of pET32a(+). Plasmids encoding b1,4-GalT and a2,3-SiaT were expressed in E. coli BL21(DE3) at 201C with 1.0 mM isopropyl b-D-thiogalactopyranoside, respectively, and their C-terminal His 6 -tagged fusion soluble proteins were purified by Co 2+ affinity chromatography (TALON Purification Kit, Clontech, Mountain View, CA, USA) according to the manufacturer's instructions. The MW of the proteins were analyzed and determined by 12% SDS-PAGE. Protein concentrations also determined by the Bradford assay using bovine serum albumin as a standard. 23 Enzymatic effect of b-1,4-GalT and a-2,3 Sia T in NeuAca2,3-Gal b-1,4 GlcNAc Protocols used to enzymatically synthesize Galb1,4-GlcNAc (4) and NeuAca2,3 Galb1,4-GlcNAc (5) using b1,4-GalT and a2,3-SiaT were performed as published elsewhere. 11, 12, 24 Compound 3 was tested in an enzymatic reaction with b1,4-GalT in an attempt to prolong the production of 4. The galactosylation reaction was performed with 50 mM HEPES, pH 7.6, 1.0 mM MnCl 2 , 40 mM 3, 20 mM UDP-Gal and 100 mM purified b1,4-GalT. The reaction mixtures were incubated at 30 1C for 24 h and terminated by boiling for 2 min. The samples were analyzed by thin layer chromatography (TLC) on silica-60 TLC plates (Merck, Darmstadt, Germany) after purification with DOWEX 1X8-200 chloride anion exchange resin and sephadex G10 resin. 25 A typical sialylation reaction of a2,3-SiaTon purified 4 was performed in 100 mM Tris-HCl (pH 8.5) containing 20 mM MgCl 2 , 10 mM 4, 10 mM CMP-NeuAc, and 100 mM purified a2,3-SiaT. The reactions were allowed to proceed for 12 h at 30 1C, and compound 5 was analyzed by TLC. For the purification of 4 and 5, three kinds of method were used. After adsorbed using SA1500 charcoal (MeadWestvaco, Richmond, VA, USA), those compounds were washed with DW and then eluted by 40% EtOH. Thus, DOWEX 1X8-200 NaCl (0.1 M) anion exchange resin and sephadex G10 resin using FPLC were used to remove salt and small impurity further. Finally, all new compounds, including 4 and 5, were characterized by liquid chromatography-MS (prep. LC-MSD, 1100+G1958, Agilent Technologies, Palo Alto, CA, USA) and NMR analysis.
In vitro galactosylation and sialylation reactions with vancomycin and pseudo-vancomycin
The galactosylation reactions of 1 and 2 were performed respectively in 20 ml of buffer (50 mM HEPES pH 7.6, 5.0 mM MnCl 2 , 5.0 mM 1 or 2) with 10 mM UDPGal and 100 mM purified b1,4-GalT at 30 1C. The reaction mixtures were sampled at various time points. The incubation was terminated by boiling for 5 and 15 min of centrifugation at 13 000 r.p.m. The supernatants, including galactosylated 1 and 2 (8 and 6), were monitored with HPLC analysis using an Adsorbosphere strong anion-exchange analytical columns (Cole-Parmer, Vernon Hills, IL, USA; Hypersil ODS 4.6Â250 mm, 5 mm particle size and Chromolith performance RP-18e, 4.6Â100 mm). Furthermore, continuous sialylation reactions of 6 and 8 were performed respectively in 20 ml of buffer (100 mM Tris-HCl pH 8.5, 5.0 mM MgCl 2 , 5.0 mM 6 or 8) with 10 mM CMPNeuAc and 100 mM purified a2,3-SiaT at 30 1C. The reaction mixtures were sampled at various time points, and the supernatants, including the sialylated compounds 6 and 8 (7 and 9), were monitored by HPLC as described above.
Purification of vancomycin derivatives (6, 7, 8 and 9) and analytical methods Two successive preparative HPLC purifications with a mixed solvent system were preformed to isolate vancomycin derivatives using SHIMADZU SPD10Avp (source Q15 resin 200 ml, FineLine Pilot 35 column, Amersham Biosciences, Piscataway, NJ, USA) and K-prep HPLC (ODS-AP 300-S10/20 30fÂ500 mm column, Kyoto Chromato, Kyoto, Japan). First, water and an aqueous solution containing 1.0 M tetraethylammonium borate were used as eluents, with the concentration of tetraethylammonium borate ranging from 0 to 80%. Then, 10 mM TEAA and acetonitrile were used as eluents, with the concentration of acetonitrile ranging from 0 to 100%. The purified products were analyzed by analytical HPLC after lyophilization, and the purity of the vancomycin derivatives was proven to be more than 98% by HPLC peak integration. All vancomycin derivatives were characterized by LC-MS.
NMR spectroscopy
NMR spectroscopy was achieved by the Korea Basic Science Institute (KBSI, Ochang, Korea). The lyophilized samples were dissolved in 250 ml of deuterium oxide and 30 ml of DMSO-d6 was added. The samples were transferred to the 5 mm thin wall micro-BMS-3 NMR tube (Shigemi, Alison Park, PA, USA). All NMR spectra were recorded at 298 K using Avance II 900 and Avance II 800 spectrophotometer (Bruker-Biospin, Billerica, MA, USA). Conventional twodimensional experiments 1 H-1 H correlation spectroscopy, TOCSY (and 70 ms z-filtered DIPSI-2 sequence was used for Hartmann-Hahn mixing), All NMR data were processed using TopSpin 2.1 (Bruker-Biospin) software on a Linuxoperating PC workstation.
